Renalytix plc

("Renalytix" or the "Company")

Renalytix Announces Management Change - Howard Doran Promoted to President

LONDON and SALT LAKE CITY, 18 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that Howard Doran, who has served as the Company's Chief Business Officer since September 2023, has been appointed as President, effective April 30, 2024. Thomas McLain, who has served as the Company's President since July 2019, is stepping down effective that date.

James McCullough, Renalytix CEO, said:

"We thank Tom for his many accomplishments in helping Renalytix achieve the tri-fecta of broad insurance coverage, FDA regulatory approval and real-world outcomes evidence that now positions KidneyIntelX for commercial adoption.

"Howard assumes the position of President to lead the global sales effort having now built our sales team from individuals with leading industry sales track records."  

For further information, please contact:

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.